Table 1.

Inclusion and exclusion criteria

Inclusion criteria

Castration-resistant metastatic prostate cancer

Age > 18 years

RLT using 177Lu-PSMA-617

Documented progressive disease prior to the first cycle according to PSA and/or imaging

History of therapy with abiraterone or enzalutamide or both, or documented progressive disease under ongoing therapy with one of these agents (prior to 177Lu-PSMA)

PSMA-positive metastases (in PSMA scan)

ECOG 0–2

GFR > 40 mg/dl

Have a follow-up at least 6 months from the time of the first cycle, or the patient died within this time

Exclusion criteria

Hormone-sensitive prostate cancer

Active malignancy other than prostate cancer